Core Viewpoint - The company, Giant Biological, has issued a strong statement denying allegations of product fraud related to its brand, Kefu Mei, specifically regarding the collagen content in its products. The company asserts that all products comply with regulatory standards and have undergone rigorous testing to ensure quality and safety [4][8]. Group 1: Company Response - Giant Biological firmly rejects accusations of serious fraud and insists that all product formulations are accurately labeled and compliant with relevant regulations [4][6]. - The company conducted multiple tests on its products, confirming that the collagen content exceeds 0.1%, contradicting claims of a mere 0.0177% [5][6]. - A detailed report of the testing results shows collagen content in various batches of the product, with values ranging from 0.27% to 0.28% [5]. Group 2: Allegations and Background - The controversy began when a social media account, "Big Mouth Doctor Yan Research Institute," published an article questioning the authenticity of Giant Biological's collagen products, claiming they lacked essential amino acids [9][10]. - The article's author, who claims to be a PhD from the University of Hong Kong, used high-precision HPLC methods to assert that the collagen content was significantly lower than advertised [10][14]. - The allegations have sparked widespread industry attention and concern regarding the integrity of the collagen market [9][10]. Group 3: Financial Performance - Giant Biological reported a revenue of 5.539 billion yuan for 2024, marking a year-on-year increase of 57.17%, with a net profit of 2.062 billion yuan, up 42.06% [25]. - The company's revenue is primarily driven by its professional skincare and health food segments, with its two main brands, Kefu Mei and Keli Jin, generating over 50 billion yuan, accounting for 97.2% of total revenue [25]. Group 4: Market Impact - Following the allegations, Giant Biological's stock price fell by 5.72%, with a market capitalization of 821.38 billion HKD as of May 23 [26].

Core Viewpoint - Huaxi Biological criticized ten research reports from nine brokerages, claiming they misled the market by promoting a "hyaluronic acid obsolescence theory" in favor of recombinant collagen products [2][3][5] Group 1: Research Reports Criticism - Huaxi Biological specifically named four reports from brokerages including Huatai Securities and Anxin Securities, which emphasized the advantages of recombinant collagen over hyaluronic acid in terms of efficacy and safety [3][5] - The reports in question did not explicitly use the term "obsolete" but suggested that collagen had superior applications in certain scenarios [5] - Huaxi Biological's article indicated that the emergence of the "hyaluronic acid obsolescence" narrative was driven by "restless capital" seeking new investment themes [3][9] Group 2: Timeline and Context - The criticism of the research reports is rooted in a timeline starting from 2022, when the recombinant collagen concept gained traction in the capital market [7][10] - Huaxi Biological itself entered the recombinant collagen market in April 2022 by acquiring a 51% stake in Beijing Yierkang Biological Engineering for 233 million yuan [9] - The reports were published between 2022 and 2024, with the earliest being from August 2022 and the latest from February 2024 [8] Group 3: Regulatory and Compliance Issues - The article raised questions about the compliance and independence of the research reports, referencing the "Interim Regulations on the Release of Securities Research Reports" which mandates objectivity and fairness [10][11] - There were indications that some brokerages had deleted the criticized reports from the WIND platform, although they remained accessible on other platforms like Choice [5][11] - The production process of research reports involves ensuring data legality and undergoing compliance checks before publication, highlighting the importance of rigorous standards in the industry [11]

Core Viewpoint - The article discusses the conflict between Huaxi Biological and several securities firms regarding the comparison of hyaluronic acid and recombinant collagen protein, with Huaxi asserting that the notion of hyaluronic acid being outdated is a misleading narrative driven by "restless capital" [2][11]. Summary by Sections Company Background - Huaxi Biological, once a darling of the capital market, saw its stock peak at 313.1 yuan and market capitalization exceed 150 billion yuan, but has since experienced a significant decline, with its stock price dropping to 52.61 yuan and market cap to 25.3 billion yuan as of May 21 [3][12]. Market Dynamics - The rise of recombinant collagen protein companies like Juzhi Biological and Jinbo Biological has shifted capital focus, with these companies achieving record highs in stock prices [4][14]. - Huaxi Biological's performance has been declining, particularly in its functional skincare segment, while the recombinant collagen protein sector is experiencing rapid growth [4][20]. Securities Firms' Reports - Huaxi Biological criticized reports from nine securities firms that favor recombinant collagen over hyaluronic acid, claiming these reports mislead the market [6][9]. - Specific reports from Huatai Securities, Guojin Securities, and others highlighted the advantages of recombinant collagen, such as its biological features and safety, which Huaxi disputes [7][8]. Industry Trends - The market for recombinant collagen products in China is projected to grow at a compound annual growth rate of 44.93%, reaching 58.57 billion yuan by 2025 [12]. - Huaxi Biological's sales of hyaluronic acid accounted for 44% of the global market in 2021, but its revenue has been declining due to challenges in its functional skincare business [12][17]. Financial Performance - Huaxi Biological's revenue and net profit have been declining, with 2023 revenue at 6.08 billion yuan and a net profit of 593 million yuan, reflecting a year-on-year decrease of 4.45% and 38.97%, respectively [17][18]. - The company's functional skincare revenue peaked in 2022 but has since dropped, leading to overall performance issues [17][19]. Strategic Response - In response to declining performance, Huaxi Biological is restructuring its management and focusing on core competencies, including a shift in branding and operational strategies [19][20]. - The company has also made acquisitions to enter the collagen market, although its recent acquisition has not yet proven profitable [20]. Competitive Landscape - The article notes that both hyaluronic acid and recombinant collagen have their respective advantages, with hyaluronic acid still holding a competitive edge in certain applications despite market challenges [21].

Core Viewpoint - The article discusses the conflict between Huaxi Biological and several brokerage firms regarding the comparison of hyaluronic acid and recombinant collagen protein, with Huaxi asserting that the notion of hyaluronic acid being outdated is a misleading narrative driven by "restless capital" [1][9]. Group 1: Company Performance - Huaxi Biological's stock price peaked at 313.1 yuan with a market value exceeding 150 billion yuan, but as of May 21, it has plummeted to 52.61 yuan, with a market value of only 25.3 billion yuan, representing a loss of over 120 billion yuan in market capitalization [2][10]. - The company's revenue for 2023 and 2024 was 6.076 billion yuan and 5.371 billion yuan, respectively, showing a year-on-year decline of 4.45% and 11.61% [14]. - The net profit attributable to shareholders for the same years was 593 million yuan and 174 million yuan, reflecting a significant decline of 38.97% and 70.59% [14]. Group 2: Market Dynamics - The market is witnessing a shift in focus from hyaluronic acid to recombinant collagen protein, with companies like Juzhi Biological and Jinbo Biological experiencing significant stock price increases and strong revenue growth [12][17]. - The recombinant collagen protein market in China is projected to grow at a compound annual growth rate of 44.93%, reaching 58.57 billion yuan by 2025 [9]. Group 3: Industry Comparison - Huaxi Biological argues that the claims made by brokerage reports regarding the superiority of recombinant collagen protein over hyaluronic acid are misleading and lack scientific backing [5][18]. - Both hyaluronic acid and recombinant collagen protein have their respective advantages in different applications, with hyaluronic acid still holding competitive strength due to its established market presence [18]. Group 4: Company Strategy - In response to declining performance, Huaxi Biological is restructuring its management and focusing on core competencies, including a renewed emphasis on its strengths in hyaluronic acid [16]. - The company has also made strategic acquisitions, such as a 51% stake in Beijing Yierkang Biological Engineering, to enter the animal-derived collagen protein market, although this subsidiary reported losses in 2024 [17].

Core Viewpoint - Huaxi Biological (688363.SZ) criticizes certain brokerage reports for misleading the market regarding the hyaluronic acid (HA) industry, claiming that these reports promote the idea that HA is outdated and misrepresent its value compared to recombinant collagen [1][2][5] Group 1: Criticism of Brokerage Reports - Huaxi Biological specifically names brokerages such as Western Securities, Anxin Securities, and Xinda Securities, accusing them of publishing misleading conclusions that favor recombinant collagen over hyaluronic acid [1][2][4] - The company argues that these reports distort scientific facts and mislead consumers, damaging the trust in the Chinese biotechnology and medical aesthetics industry [1][6] - Huaxi Biological emphasizes the importance of maintaining a fair competitive environment and the integrity of scientific information in the industry [1][6] Group 2: Market Dynamics and Competition - The criticism from Huaxi Biological is seen as a response to the rising competition from Juzhi Biological (02367.HK), which focuses on recombinant collagen and has been gaining market traction [1][8][12] - Huaxi Biological's performance has been declining, with projected revenues and net profits for 2024 showing significant decreases compared to previous years, while Juzhi Biological has experienced substantial growth [10][12] - The company highlights that the narrative of HA being outdated is a construct of "restless capital" aiming to shift focus to new market trends, which undermines the established value of HA [13][14] Group 3: Industry Support and Response - Following Huaxi Biological's statements, two industry associations, the China Fragrance and Cosmetic Industry Association and the China Aesthetic Medicine Association, issued a joint initiative advocating for scientific integrity and ethical marketing practices [7] - Huaxi Biological reports that many institutions have retracted erroneous reports and some have issued apologies, indicating a recognition of the misleading nature of the previous analyses [6][12] - The company maintains ongoing communication with brokerage firms regarding the accuracy of research reports and their implications for the industry [6][12]

Core Viewpoint - The article discusses the conflict between Huaxi Biological and several brokerage firms regarding the comparison of hyaluronic acid and recombinant collagen protein, with Huaxi asserting that the notion of hyaluronic acid being outdated is misleading and driven by "restless capital" [1][7]. Company Overview - Huaxi Biological specializes in hyaluronic acid-related products and has faced significant stock price and market capitalization declines since reaching a peak in July 2021, with its stock price dropping from 313.1 yuan to 52.61 yuan as of May 21, 2023, resulting in a market cap reduction from over 1500 billion yuan to 253 billion yuan [2][8]. - The company has reported continuous revenue declines, with revenues of 60.76 billion yuan and 53.71 billion yuan for 2023 and 2024, respectively, representing year-on-year decreases of 4.45% and 11.61% [10]. Industry Dynamics - The market has seen a shift in focus towards recombinant collagen protein, with companies like Juzhi Biological and Jinbo Biological experiencing significant stock price increases and revenue growth, contrasting with Huaxi's struggles [2][13]. - The recombinant collagen protein market in China is projected to grow at a compound annual growth rate of 44.93%, reaching 585.7 billion yuan by 2025 [7]. Performance Comparison - Juzhi Biological's revenues for 2022, 2023, and 2024 were 23.75 billion yuan, 35.26 billion yuan, and 55.39 billion yuan, respectively, with year-on-year growth rates around 50% [13]. - Jinbo Biological's revenues during the same period were 3.9 billion yuan, 7.8 billion yuan, and 14.43 billion yuan, with growth rates of 67.15%, 99.97%, and 84.92% [13]. Regulatory and Market Response - Huaxi Biological has reported the brokerage firms to the China Securities Regulatory Commission for allegedly misleading reports that could distort market perceptions [1][3]. - The company has emphasized the need for a healthy industry ecosystem and has engaged with industry associations to advocate for a return to scientific principles in the market [5][7].

Core Viewpoint - The article highlights a conflict in the biopharmaceutical industry regarding the competition between hyaluronic acid and recombinant collagen, with Huaxi Biological criticizing the notion that hyaluronic acid is outdated, which they attribute to capital-driven speculation [1][4]. Company Performance - Huaxi Biological's performance has declined significantly, with projected revenue for 2024 expected to decrease by 11.61% and net profit to drop by 70.59%, resulting in a market capitalization loss of over 100 billion [1][6]. - In contrast, Juzhi Biological has experienced substantial growth, with a projected revenue increase of 57.2% and net profit growth of 42.4% for 2024, leading to a doubling of its market capitalization [1][6]. Market Dynamics - The article discusses the contrasting market performances of Huaxi Biological and Juzhi Biological, indicating a clear divide in the industry, with Huaxi's stock price falling over 80% from its peak of 309.43 yuan per share in July 2021 to 53.08 yuan per share as of May 20, 2025, resulting in a market cap of less than 25.6 billion [9][6]. - Juzhi Biological's stock has seen a significant increase, reaching a peak of 86.45 HKD, representing a cumulative rise of over 44% from approximately 60 HKD at the end of 2024 [8][6].

Core Viewpoint - The article highlights the conflict between Huaxi Biological and several brokerage firms that support Juzi Biological, criticizing the notion that sodium hyaluronate is outdated and emphasizing the ongoing relevance of hyaluronic acid in the beauty and medical aesthetics industry [1][3]. Company Performance - Huaxi Biological's market capitalization has significantly decreased from over 140 billion yuan in 2021 to approximately 25 billion yuan currently, while Juzi Biological's stock has surged nearly 70% in 2024, elevating its founders to the status of the richest individuals in Shaanxi [2]. - In 2024, Huaxi Biological reported its worst performance since going public, with annual revenue of 5.371 billion yuan, a decline of 11.6% year-on-year, and a net profit of 164 million yuan, down 72.27% [2]. - Juzi Biological, in contrast, has shown robust growth since 2019, with 2024 revenue reaching 5.539 billion yuan, a year-on-year increase of 57.17%, and a net profit of 2.062 billion yuan, up 42.06% [2]. Market Trends - The market is increasingly favoring the field of recombinant collagen due to its excellent biocompatibility and biodegradability, with projections indicating that the collagen-based skincare market may surpass that of hyaluronic acid by 2026, with a compound annual growth rate of 52.6% [3]. - Despite the rise of recombinant collagen, hyaluronic acid remains irreplaceable in the medical aesthetics sector, particularly in filling procedures, and Huaxi Biological continues to hold a competitive edge in this area [3]. Industry Dynamics - Several brokerage firms, including Huafu Securities and Debon Securities, have retracted their reports that were criticized by Huaxi Biological, indicating the contentious nature of the market's perception of recombinant collagen [4]. - The development of recombinant collagen is still in its early stages, with high raw material costs and insufficient research on its applications, suggesting that both hyaluronic acid and recombinant collagen may coexist in the market to meet diverse consumer needs [4].

Core Viewpoint - Huaxi Biological Technology Co., Ltd. (688363.SH) criticized certain brokerage reports for misleading the market regarding the comparison between hyaluronic acid and recombinant collagen, claiming these reports lack scientific basis and are intended to promote a competing product [1][3][6] Group 1: Company Response - Huaxi Biological reported that it has communicated with regulatory authorities regarding the misleading content in brokerage reports and received apologies from some institutions [1][4] - The company emphasized that the reports are part of a broader issue of "hasty capital" creating a false narrative in the market [3][4] - Huaxi Biological expressed disappointment that relevant parties are not engaging in scientific discussions but are instead focusing on social media commentary [4][5] Group 2: Brokerage Reports - The reports in question were authored by multiple brokerage firms, including Huatai Securities and others, which Huaxi Biological claims are biased towards a competitor, Juzhi Biological [3][6] - Analysts involved in the reports defended their work, stating that the content was compliant and based on objective public data, and denied any intent to promote Juzhi Biological [2][7][8] - The reports highlighted the advantages of recombinant collagen over hyaluronic acid in various applications, which Huaxi Biological disputes as lacking scientific evidence [3][6][8] Group 3: Market Context - In 2024, Juzhi Biological reported a revenue of 55.39 billion yuan, a 57.07% increase, surpassing Huaxi Biological's revenue of 53.71 billion yuan, which declined by 11.61% [6] - Juzhi Biological's core brand, Kefu Mei, contributed 82% of its revenue, showcasing the competitive landscape in the beauty and medical aesthetics industry [6]

Core Viewpoint - The article discusses the ongoing debate in the capital market regarding the valuation and relevance of hyaluronic acid, with Huaxi Biological refuting claims that it is outdated, labeling such views as a product of "restless capital" [1][3][9]. Group 1: Company Positioning - Huaxi Biological published an article on May 17, 2023, directly criticizing nine brokerage reports that suggested hyaluronic acid is outdated, asserting that this narrative is misleading and harmful to the industry [1][3]. - The company emphasized the importance of voicing its stance to protect the integrity of the hyaluronic acid industry, which has been developed over decades of scientific research [6][9]. - Huaxi Biological's market share in the global hyaluronic acid market was reported at 44% in 2021, with China accounting for 82% of global sales [6]. Group 2: Market Dynamics - The article highlights a shift in capital market interest from hyaluronic acid to recombinant collagen, with companies like Juzhibio gaining significant market traction [10][15]. - Juzhibio's stock price has surged nearly 70% in 2023, positioning it as a leading player in the beauty and skincare sector, while Huaxi Biological and other hyaluronic acid companies have seen declining performance [10][13]. - The market for recombinant collagen is projected to grow at a compound annual growth rate (CAGR) of 44.93%, reaching 585.7 billion yuan by 2025 [16]. Group 3: Industry Trends - The article notes that the beauty and skincare industry is experiencing rapid shifts, with companies needing to adapt to changing consumer preferences and capital market trends [2][15]. - Huaxi Biological has begun to diversify its product offerings, launching multiple collagen products and obtaining medical device registrations to stay competitive [17]. - The competitive landscape for recombinant collagen is intensifying, with various companies entering the market, indicating that maintaining a leading position will be challenging for Juzhibio [16][17].